Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties

• Published in: American journal of transplantation Vol. 5; no. 3; pp. 443 - 453
• Main Authors: Larsen, Christian P., Pearson, Thomas C., Adams, Andrew B., Tso, Paul, Shirasugi, Nozomu, StrobertM, Elizabeth, Anderson, Dan, Cowan, Shannon, Price, Karen, Naemura, Joseph, Emswiler, John, Greene, JoAnne, Turk, Lori Ann, Bajorath, Jurgen, Townsend, Robert, Hagerty, David, Linsley, Peter S., Peach, Robert J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Munksgaard International Publishers 01.03.2005
• Subjects: Abatacept; Animals; Antigens, CD - immunology; Antigens, Differentiation - genetics; Antigens, Differentiation - immunology; Antigens, Differentiation - pharmacology; B7-2 Antigen; CD28; CD28 Antigens - immunology; Cell Proliferation - drug effects; CHO Cells; co‐stimulation; Cricetinae; Cricetulus; CTLA-4 Antigen; CTLA4‐lg; Humans; Immunoconjugates - genetics; Immunoconjugates - immunology; Kinetics; Membrane Glycoproteins - immunology; non‐human primate; Protein Engineering; T-Lymphocytes - drug effects; transplantation

Current success in organ transplantation is dependent upon the use of calcineurin‐inhibitor‐based immunosuppressive regimens. Unfortunately, current immunotherapy targets molecules with ubiquitous expression resulting in devastating non‐immune side effects. T‐cell costimulation has been identified a...